ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

ONT Oxford Nanopore Technologies Plc

154.70
0.50 (0.32%)
Last Updated: 08:23:58
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Oxford Nanopore Technologies Plc LSE:ONT London Ordinary Share GB00BP6S8Z30 ORD GBP0.0001
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.50 0.32% 154.70 154.20 155.20 155.60 154.20 155.50 689,673 08:23:58
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Coml Physical, Biologcl Resh 169.67M -154.51M -0.1641 -9.40 1.45B
Oxford Nanopore Technologies Plc is listed in the Coml Physical, Biologcl Resh sector of the London Stock Exchange with ticker ONT. The last closing price for Oxford Nanopore Technolo... was 154.20p. Over the last year, Oxford Nanopore Technolo... shares have traded in a share price range of 86.00p to 211.40p.

Oxford Nanopore Technolo... currently has 941,455,189 shares in issue. The market capitalisation of Oxford Nanopore Technolo... is £1.45 billion. Oxford Nanopore Technolo... has a price to earnings ratio (PE ratio) of -9.40.

Oxford Nanopore Technolo... Share Discussion Threads

Showing 3376 to 3398 of 3600 messages
Chat Pages: 144  143  142  141  140  139  138  137  136  135  134  133  Older
DateSubjectAuthorDiscuss
15/8/2024
07:19
I see Oxford are engaged on mPOX virus outbreak.

Innovative protocols, such as the metagenomic workflow developed by teams at

@GSTTnhs

supported by

@nanopore

will play a crucial role in characterising and containing the #mPoxvirus

seball
15/8/2024
06:08
TR-1 G42 Diluted.
Go from 5.58% to 4.7%

bamboo2
14/8/2024
07:22
Hadn't realised the interest that Oracle established in ONT,while giving access to their cloud tech. I don't know how relevant but the owner/CEO of Oracle is building a massive institute on the Oxford Science Park that bears his name, with the object of cracking cancer once and for all. Ellison is AFAIK, among the five wealthiest peeps in the US. Correct me if I'm wrong on any of this please!
brucie5
14/8/2024
07:06
NOVO upping their stake. Now hold over 5%. This is only going up. Good luck all
seball
09/8/2024
19:53
Need to look more closely when have a chance as some, if not all, of the % reduction is dilution.
Not necessarily all sales.

p1nkfish
09/8/2024
19:42
Oracle were the owner through Delphi.
p1nkfish
09/8/2024
16:56
TR-1

Delphi diluted to under 4%
Gone from 4.44% to 3.75%

bamboo2
09/8/2024
10:54
There was a large [15m?]trade at the lows under a £1
It could possibly be these that are being flipped.

bamboo2
09/8/2024
09:36
Yes,115-120 seems a solid support level.Unfortunately,providing Novo with stock at 120p is dictating the price for now.
steeplejack
08/8/2024
12:32
Yes. In the current market one might as well stick a pin in the chart as far as short term movements go. But I believe that the bottom is now in and therefore anything accumulated below £1.20 is likely to be viewed as excellent value within 2 years.
brucie5
08/8/2024
10:59
Cutting-edge sequencing technology halts outbreak of drug-resistant infection in Wellington neonatal intensive care unit
07 August 2024



A team of researchers from the Institute of Environmental Science and Research (ESR) and Awanui Labs Wellington successfully implemented a cutting-edge nanopore genomic surveillance system, halting a drug-resistant infectious outbreak in a Wellington-based neonatal intensive care unit (NICU). This advanced technology enabled the early detection and control of an outbreak of methicillin-resistant Staphylococcus aureus (MRSA), helping to protect highly vulnerable patients.

bamboo2
07/8/2024
19:39
IPO total holding has fallen due to NOVO as the old notification didn't allow for the Australian IP2IPO holding that IPO has control of the voting rights for. At first look it appears as an increase but is actually a dilution.
p1nkfish
07/8/2024
17:08
Deleted.
Holdings from Novo .

eeza
07/8/2024
17:05
IPG upped their stake
mirabeau
06/8/2024
11:53
Decent recovery to the 1.20 placing price. I will be looking to add as new funds become available.
brucie5
06/8/2024
10:54
Good point steeple. I'm suspicious there are moves in the UK market normal plebs can't understand as not sitting at the table being consulted. Big investors are likely to be consulted and its not past any of them not to front run decisions.
p1nkfish
06/8/2024
09:54
Inversely,there̵7;s a case for realising gains this financial year and carrying forward capital losses to offset against future profits.The Government are highly unlikely to impose a radical change of capital gains tax in the current financial year this October They could but they’d be an uproar,it'd make a nonsense of tax planning.New rulings more likely to apply to the 25/26 tax year.

I guess the new regime will give tax free spreadbetting a boost.ISAs will become even more treasured.Like all such tax grabbing plans,they’ll be consequences and they won’t be that healthy.Outside of the ISA wrapper share dealings could sharply reduce.Of course,there’s nothing to say that the Labour government won’t try to plug the gaps by reducing the annual ISA allowances.I’m just pleased to be able to contribute to those gold plated civil servant pensions.

steeplejack
06/8/2024
08:28
Question - how much 2nd guessing Reeves CGT plans accounts for losses being crystallised as soon as possible rather than in the early new year to end of March?

Those losses could be of increased value if they can be offset at 40 pc type future tax take in a new regime rather than under the current CGT regime.

p1nkfish
05/8/2024
19:30
Singapore’s Precision Medicine Program to Analyze 10K Genomes With Nanopore Sequencing
Aug 05, 2024


[use link for complete article]

NEW YORK – Oxford Nanopore Technologies said Monday that it will participate in Singapore’s National Precision Medicine (NPM) program to help improve the understanding of the country’s genetic architecture.

Financial details of the deal were not disclosed.

Oxford Nanopore said it will sequence 10,000 genomes representing Singapore’s diverse population, including Malay, Indian, and Chinese communities, as part of the second phase of the NPM program. The goal is to develop a comprehensive structural variant catalog of the country's three major ethnic groups. The company’s portion of the project, which started in mid-2024 and will run up to 12 months, will be carried out by genomics service provider NovogeneAIT using the PromethIon 48 device for sequencing.

Led by Precision Health Research Singapore (PRECISE), an organization established by the Singapore government, Phase II of the three-phase NPM program was kicked off in 2021 to analyze the genetic makeup of 100,000 healthy Singaporeans and up to 50,000 individuals with specific diseases. The country hopes to harness the genetic insights from the project to inform precision medicine for its populations.

"We are excited to collaborate with Singapore’s National Precision Medicine (NPM) program to create one of the most extensive and inclusive reference genome datasets globally," Oxford Nanopore CEO Gordon Sanghera said in a statement. "This collaboration not only enhances our commitment to precision healthcare but also strategically positions Singapore as a pivotal hub for genomics in the Asia Pacific, fostering significant advancements in medical research and healthcare outcomes."

Oxford Nanopore said it has made strategic investments in Singapore, its commercial hub for Asia Pacific, including a recent expansion of its lab facilities in the country and deploying sequencers at the Science Centre Singapore and the Singapore Institute of Technology for use in high school, undergraduate, and adult education programs.

Earlier this year, Oxford Nanopore competitor Pacific Biosciences signed a similar deal with the national Estonian Biobank, which will use the company's Revio HiFi sequencing system to analyze 10,000 human genomes from its biorepository.

bamboo2
05/8/2024
15:53
Or just study what I do.


And do the opposite.
;)

brucie5
05/8/2024
13:16
Chance of some wider relief rally within next month (possibly to high again or a little above) but also a chance it will then be sold into taking indices down further. More than 1 leg.

ONT will be fine imho for those with enough patience. Some damage being done to wider markets though that won't repair very quickly. Might it be a 12-36 month repair job? Too many fragilities.

Cash is king, time to wait for confirmation the storm(s) have past before getting excited to buy much of anything imho unless the buyer is a good trader or very patient.

IPO in the toilet at higher than average volume. They should be able to buy a few back.

p1nkfish
05/8/2024
08:16
Not sure it will be good ultimately as the only time they "slash" rates is when they have dropped the ball and the system is excessively fragile or already heading into the toilet and they are trying to slow the rate of decline and depth. Tends to scare the horses if they move off schedule and cut deep and fast. Clever money waits until the dust has settled.
p1nkfish
05/8/2024
07:58
Interesting news this morning, particularly when the Singapore sovereign wealth fund had been selling down their stake (GIC private). As to the share price holding up well, most US holders will still be asleep, so I wouldn't call it too early. If rates are slashed then it should be positive for risk assets though, but could be some carnage in the meantime...
74tom
Chat Pages: 144  143  142  141  140  139  138  137  136  135  134  133  Older

Your Recent History

Delayed Upgrade Clock